Tiered immunotoxicity testing strategies have been developed in both rats and mice. These tiered systems focus on the detection of compound-induced immunosuppression. Clinical relevance has clearly been demonstrated in the case of pharmaceuticals for which the primary aim is to induce immunosuppression in organ transplant recipients. Validation for pharmaceuticals is still ongoing.
DescotesJ. Immunotoxicity of pharmaceuticals: an introduction. Drug Inf J.1996;30:271–274.
2.
BasketterDABremmerJNKammüllerMEKawabataTKimberILovelessSEMagdaSPalTHMStringerDAVohrH-W. The identification of chemicals with sensitizing or immunosuppressive properties in routine toxicology. Food Chem Toxicol.1994; 32:289–296.
3.
LusterMIMunsonAEThomasPTHolsappleMPFentersJDWhiteKLLauerLDGermolecDRRosenthalGJDeanJH. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fund Appl Toxicol.1988;10:2–19.
4.
VosJG. Immune suppression as related to toxicology. Crit Rev Toxicol.1977;5:67–101.
5.
VosJG. Immunotoxicity assessment: screening and function studies. Arch Toxicol.1980 Suppl. 4:95–108.
6.
Van LoverenHVosJG. Immunotoxicological considerations: a practical approach to immunotoxicity testing in the rat. In: Advances in Applied Toxicology.DayanADPaineAJ, eds. Taylor & Francis Ltd; 1989:143–163.
7.
VosJGSmialowiczRJVan LoverenH. Animal models for assessment. In: Immunotoxicology and Immunopharmacology.Second Edition. DeanJHLusterMIMunsonAE, eds. Raven Press Ltd: New York; 1994:19–30.
8.
KoeterHBWM. International harmonisation of immunotoxicity testing. Hum Exp Toxicol.1995;14: 151–154.
9.
De WaalEJTimmermanHHDortantPMKrajncMAMVan LoverenH. Investigation of a screening battery for immunotoxicity of pharmaceuticals within a 28-day oral toxicity study using azathioprine and cyclosporin A as model compounds. Reg Toxicol Pharmacol.1995;21:327–338.
10.
Van LoverenHGianottenNHendriksenCFMSchuurmanH-JVan der LaanJW. Assessment of immunotoxicity of buprenorphine. Lab Animals.1994;28:355–363.
11.
Van der LaanJWKrajncEIKrajnc-FrankenMAMVan LoverenH. Immunotoxicological screening of morphine and methadone in an extended 28-day study in rats. Int J Immunopharmacol.1995;17:535–543.
12.
De WaalEJDe JongWVan Der VlietHVerlaanBVan LoverenH. An immunotoxicity screening study on salmeterol in rats. Int J Immunopharmacol.1997.
13.
MaiselASMurrayDPolizziSMotulskyHJBroddeOEVan TitsLJHMichelMC. Does verapamil act as an immunomodulatory drug in vivo?. Immunopharmacol.1991;22:85–92.
14.
LusterIPortierChPaitDGWhiteKLGenningsChMunsonAERosenthalGJ. Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fund Appl Toxicol.1992;18:200–210.
15.
LusterIPortierChPaitDGRosenthalGJGermolecDRCorsiniEBlaylockBLPollockPKouchiYCraigWWhiteKLMunsonAECommentE. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fund Appl Toxicol.1993;21:71–82.
16.
Van LoverenH. Host resistance models. Hum Exp Toxicol.1995;14:137–140.
17.
NeumannDA. Immunotoxicity testing and risk assessment: Summmary of a 1994 Workshop. Food Chem Toxicol.1995;33:887–894.
18.
StahlmannRKorteMVan LoverenHVosJGThielRNeubertD. Abnormal thymus development and impaired function of the immune system in rats after prenatal exposure to aciclovir. Arch Toxicol.1992;66:551–559.
19.
SchlumpfMLichtensteigerWVan LoverenH. Impaired host resistance to Trichinella spiralis as a consequence of prenatal treatment of rats with diazepam. Toxicology.1994;94:223–230.
